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Abstract 
The function of local research ethics committees is to consider the ethics of research 
proposals using human participants. After approval has been given, there is no 
comprehensive system in place to monitor research and ensure that 
recommendations are carried out. Some suggest that research ethics committees 
are ideally placed to fulfil this function by carrying out random monitoring of research 
they have reviewed. The health service guideline creating local research ethics 
committees is under review.1 This paper argues that increasing the monitoring role 
of ethics committees in the present climate would be inappropriate. This is due to the 
large workload of the committees, their voluntary nature and the change a monitoring 
role might cause to the relationship between researcher and ethics committee, which 
might herald an increasing recourse to judicial review. An overhaul of the system 
would be necessary in order for ethics committees adequately to fulfil a monitoring 
function. 
 
Introduction 
In 1991 a health service guideline was issued stating that “every health district 
should have a local research ethics committee to advise NHS bodies on the ethical 
acceptability of research proposals involving human subjects”.1 This paper considers 
whether their role is indeed limited to a consideration of “research proposals 
involving human subjects”, or is gradually evolving to incorporate a duty to review 
and monitor the research after the initial approval.  
 
Local research ethics committee (LREC) members come from a variety of 
backgrounds and rarely receive recompense for the considerable time they spend 
reading and deliberating over research proposals. The LREC workload is extensive.2 
Funding is often inadequate and many committees have resorted to charging for 
review of commercially sponsored proposals in order to raise funds for training and 
administration.3 This contrasts sharply with international equivalents where the 
administrative and funding systems are often more conducive to a monitoring role. 
 
Nevertheless, it is conceivable that pressure will be brought to bear on LRECs to 
increase their monitoring function. Though there are a variety of monitoring systems 
within the UK, we currently lack a comprehensive system to which all health care 
research is subjected. Thus, in isolation, the Medical Controls Agency monitors 
serious adverse events in clinical trials, the Research and Development Directorate 
of the NHS Executive monitor management and finance, and research ethics 
committees monitor progress of the research they review. There are three loosely 
defined categories which LRECs could adopt to try and protect research participants 
when monitoring research after approving a protocol: 
 
- detecting fraudulent research; 
- collecting progress reports and reviewing changes 
to protocols, and 
- proactive monitoring through questionnaire 
and/or visitation of research site 
In relation to the first category, detecting fraudulent research involves an expensive 
policing role, largely inappropriate for LRECs which are concerned with facilitating 
scientifically valid research and protecting the dignity and welfare of research 
participants. The current monitoring processes of LRECs are largely confined to the 
second category, collecting progress reports and reviewing changes to protocols, 
with the exception of a small number of committees which have extended their 
monitoring activities to the third category. Local research ethics committees have 
access to the original research protocol and are arguably in an ideal position to 
increase their monitoring function. However, though there is evident value in 
proactive LREC monitoring, a greater commitment to adequate resourcing and 
further professional guidance is needed before it can be more widely adopted. 
 
Limited role of ethics committees in detecting fraudulent research 
Fraudulent research has attracted significant media attention, not least because it 
has proved remarkably difficult to detect. Career advancement is partially dependent 
on research publications, and the funding obtained as a result makes fabrication a  
tempting shortcut to some. In 1996 a researcher forged two letters purporting to 
come from the Salford research ethics committee giving approval for the research to 
go ahead4; and in November 1997 a senior physician and a former registrar of the 
Royal College of Physicians of Edinburgh were struck off for conducting a fifteen-
month fraudulent drug trial. The trial attracted significant media interest because of 
the potentially fatal consequences of doctors acting on false information.5 Again, in 
1998 a paper was withdrawn from the British Medical Journal because of a 
researcher’s misconduct and lies concerning his qualifications.6 
 
This area is currently overseen by the Medical Research Council7 together with the 
Committee on Publication Ethics,8 aided by the guidance of the Royal College of 
Physicians’ report, 1991.9 In view of the fact that fraud often involves omitting the  
review process altogether, the detecting role of LRECs is likely to remain 
insubstantial. However, in the limited circumstances where the fraudulent behaviour 
involves non-adherence to the approved protocol, it is possible that widening the role 
of LRECs to include random monitoring of research they have approved might deter, 
detect and reduce cases of research misconduct. 
 
Collecting progress reports and reviewing changes to protocols 
Professional guidelines place duties on researchers to report progress and changes 
of protocol to the relevant ethics committee(s).10 Adverse reactions in clinical 
research protocols are reported to the Medical Controls Agency (MCA). Health 
service guideline (91)5 at paragraph 2.14 also states that: 
 
“Reports to the [local research ethics] committee should also be required once 
the research is underway if there are any unusual or unexpected results which 
raise questions about the safety of the research”. 
 
However, there is no agreed operative procedure for dealing with such reports 
which, in some circumstances, are merely filed away. In the case of academic 
research protocols, in which adverse reactions are not reported to the MCA, a 
standardised procedure for dealing with reports would be especially useful. The 
Health Service Guideline (91)5 introducing the LREC system states that: 
“If it comes to the attention of a committee ... that its recommendations have 
been ignored, then the LREC should bring the matter to the attention of its 
appointing authority, ...” 
but this places no duty on the committee actively to audit investigators. The 1996 
Royal College of Physicians’ guidance, published three months after the 
International Conference on Harmonisation Good Clinical Practice guidelines, adds 
somewhat to these duties. The report recognises the impracticalities of RECs 
actively monitoring research, but encourages it as an occasional endeavour.11 
However, this guidance has only limited force for LRECs which are bound by the 
health service guideline. 
 
Inconsistent protection for research participants 
In commercially sponsored trials, a monitor is usually appointed to guard against and 
react to a range of occurrences, as is verified in the International Conference on 
Harmonisation Good Clinical Practice guidelines.12 In investigations involving drugs 
or novel equipment and trials sponsored by industry, reporting adverse events to the 
sponsor is mandatory under the Good Clinical Practice Guidelines issued by the 
Association of the British Pharmaceutical Industry (1993).13 In other types of 
research, participants are reliant on the investigators conducting the research 
according to the approved protocol and faithfully reporting any divergence or 
alteration to the LREC. In the light of those cases of fraud outlined above, this is an 
inadequate means of protecting research participants. 
 
Pressure for LRECs to increase their monitoring role 
Not only is the current monitoring system insufficient, but calls are being made to 
increase and harmonise monitoring procedures (particularly in relation to clinical 
trials) both across Europe14 and internationally. In the USA, the rules governing 
institutional review boards (which are roughly the equivalent of our research ethics 
committees) have recently come under a great deal of scrutiny. Amongst the 
recommendations in a 1998 Inspector General’s report15 was the need for a 
universal system of monitoring trials. The report suggested that institutional review 
boards could take a more active role in this. 
 
In Australia the law was amended in 1992 to require institutional ethics committees 
to monitor research projects after they received ethical approval.16 As in the UK, 
emphasis is placed on reporting by the investigator. Hence the investigator 
is required to make at least an annual report and to notify the institutional ethics 
committee of adverse effects, changes in protocol and unforeseen events. 
  
The institutional ethics committee is given the possible sanctions of withdrawing 
ethical approval or informing the governing body of the institution who can then take 
disciplinary action against the investigators. There is pressure17 for a system 
enabling audit of a random selection of research project records; the appointment of 
a member of the institutional ethics committee to act as a monitor for specific 
projects; the establishment of a subcommittee to review progress reports, and the 
establishment of a complaint-handling mechanism within the institutional ethics 
committee for research participants to contact. Further suggestions include making 
approval subject to the signed agreement of investigators to comply with the 
regulations, requiring researchers to report to the institutional ethics committee every 
six months and enforcing the publication of results. 
 
The international impetus for increased monitoring of trials by ethics committees may 
have an effect  on LRECs. However, though there are similarities in the roles of the 
various committees, it should be noted that the US and Australian committees are 
usually attached to an institution, unlike the LREC which is independent. They serve 
that institution, protecting it from legal liability. It is therefore conceivable that their 
role should not cease once the  protocol has been approved. In short, for the LREC 
to perform the duties starting to be requested of their international equivalents, a 
degree of change is needed. This is not only in terms of funding, but also in terms of 
the very nature of the independent, voluntary basis of the LREC. The Department of 
Health guidance to LRECs supports the current, limited monitoring functions of 
LRECs. As health service guideline (91)5 is currently under review, it remains to be 
seen whether the Department of Health will increase the LREC monitoring role, 
allocate it to another branch of the system such as the Research and Development 
Directorate of the NHS Executive, or allow the current divergences between the 
monitoring in clinical and non-clinical research settings to remain. 
 
Proactive monitoring through questionnaire and/or visitation of research site 
The case for extending the LREC monitoring role is based on the fact that LRECs’ 
approval of the protocol and receipt of progress reports makes them obvious 
candidates to fill an evident gap in a system designed to protect research 
participants from unethical research. Unfortunately, though sanctions are issued by 
the National Health Service (NHS) against any of its employees who initiate research 
on human subjects without REC approval, the LREC is currently in an inadequate 
position to ensure that all researchers adhere to the agreed protocol.  
 
Nevertheless, random monitoring by LRECs has proved successful, where adequate 
time and funding have been obtained. For example, the Tayside Committee on 
Medical Research Ethics18 published results of a monitoring exercise in 1997. The 
process sought to measure adherence to the approved protocol in 39 projects, 
particularly in terms of recruitment and specific requirements of the ethics committee 
(such as notification of changes and adverse reactions). This monitoring exercise 
produced startling results. In over a quarter of the projects there were divergences 
from the protocol in relation to the consent process. Though adverse events were 
reported, projects which were abandoned or late to start were vastly underreported 
(of the 39 projects, nine were abandoned and only one of these was reported to the 
committee). Neither was the ethics committee always informed of relevant changes 
to the protocol. Tayside continues randomly to monitor research projects by means 
of questionnaire and visitation.  
 
Berry,19 the chairman of Mid Downs East LREC, conducted a slightly different 
monitoring exercise. Berry selected a researcher sponsored commercially (so that 
some monitoring was already in place), and wrote to participants in order to check 
the standards by means of a questionnaire. Berry counsels that the questionnaire be 
kept short and simple and that the research participants agree to their name and 
addresses being passed to the committee before audit takes place, and that they are 
made aware that they are under no obligation to answer the questions. The 
questionnaire focused on the information received, the consent given, inducements 
received and instructions in the event of adverse effects. In this instance, the results 
showed an acceptable level of compliance. 
 
Problems with LREC monitoring 
Though there have been isolated examples of LREC monitoring, there are prohibitive 
time and resource implications to it becoming more widespread. Berry suggests that 
one option is to build the costs into fees charged to commercially sponsored 
research where this is already the practice of the LREC.  
 
Another problem relates to multicentre research ethics committee (MREC) approved 
research. Multicentre research ethics committees review research that is carried out 
in five or more LREC geographic localities. The protocol is then sent to each LREC 
in order that the committee can consider local issues. One MREC decision is good 
across the whole of the UK. Therefore, though progress reports, changes to protocol 
and adverse events should be reported to both the MREC and LREC, proactive 
monitoring could be an extremely costly and impractical process if performed by the 
MREC. For this reason it is expected that any proactive REC monitoring will be a 
local rather than a multicentre activity. Local research ethics committees might also 
be opposed to monitoring research on the basis that it may alter their relationship 
with researchers. Their current role, guiding researchers as to the ethicality of the 
protocol, would be extended into what might be perceived as a policing role. 
Disgruntled researchers may be increasingly likely to opt for legal action (in 
particular, judicial review) where they believe the process to have been unfair. This is 
all the more likely if LRECs charge a fee in order to fund their extra monitoring role, 
as this potentially creates a contract between the researcher and the health 
authority.20 Consequently, unless the reform of the health service guideline radically 
alters the current situation, LREC audit will at best be an infrequent event. 
 
Conclusion 
The guidance that LRECs should perform occasional monitoring leaves in the hands 
of the LREC the frequency and detail of the audit. However, the guidance expresses 
it as a desirable function and itis clear that some sort of monitoring system, that is 
not purely reliant on the honesty of investigators, would be desirable in protecting 
research participants. This is especially so in non clinical research where monitoring 
requirements are often far less stringent than is the case in pharmaceutically 
sponsored clinical research. Health service guideline (91)5 is currently under review 
within the Department of Health, and the monitoring duties of RECs is one issue 
under consideration. If it is decided that 
 LRECs should increase their monitoring role, the there must be some means of 
financing the administration and possibly even the reasonable expenses of LREC 
members. The appropriate role of MRECs in relation to audit, will also need to be 
clarified. To protect members from potential judicial review, the process and 
procedures should be carefully set out, covering the issues of how frequently to 
audit, what types of research to audit, and the appropriate method. If a questionnaire 
is used in the monitoring process, consensus on the appropriate format is needed. It 
must be ascertained whether the questionnaire will consider participants’ perceptions 
or the rigour with which the REC recommendations are carried out. 
It is suggested that the independent nature of ethics committees in the UK, coupled 
with their limited time, voluntary nature and large workload, make extensions of their 
current monitoring duties inappropriate. The current drive for clinical governance 
makes monitoring of research highly appropriate but, contrary to some international 
experience, it may be a role more suited to the Research and Development 
Directorate of the NHS Executive than research ethics committees. The Culyer 
report, Supporting Research and Development in the NHS,21 was critical of the 
complex funding arrangements for R&D and recommended a single explicit funding 
mechanism for both direct and indirect costs of R&D projects and programmes, 
including the costs of maintaining facilities enabling R&D programmes to take place. 
Ensuring the safety of research participants is integral in the maintenance of an 
ethical R&D programme and could therefore legitimately be placed within the ambits 
of R&D. 
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